Patterns of recurrence following radiation and ADT for pathologic lymph node positive prostate cancer: A multi-institutional study.

Background And Objective: We evaluate prognostic factors and patterns of recurrence in patients who received RT ± androgen deprivation therapy (ADT) for pathologic node-positive (pN1) prostate cancer (PCa) in a multi-institutional cohort.

Methods: Data from patients with pN1 PCa and received RT with short term (ST, ≤6 mo) or long term (LT, >6 mo) ADT were obtained from 4 academic institutions. Biochemical progression free survival (bPFS) and distant metastasis free survival (DMFS) were evaluated.

Synthesis and characterization of turmeric extract-β-cyclodextrin inclusion complexes: Metabolite profiling and antioxidant activity.

Turmeric (Curcuma longa L.) has gained significant attention for its medicinal properties, yet its therapeutic applications are often limited by low aqueous solubility and susceptibility to environmental factors. This study investigates the formulation of a curcumin-rich turmeric extract-β-cyclodextrin inclusion complex (TUE-β-CD) to enhance its bioactivity and stability.

Charge-transfer mediated J-aggregation in red emitting ultra-small-single-benzenic -fluorophore crystals.

Red emission in crystals has been observed with an ultra-small-single-benzenic -fluorophore () with a molecular weight (MW) of only 197 Da, bettering the literature report of fluorophores with the lowest MW = 252 Da. Supramolecular extensive hydrogen-bonding and J-aggregate type centrosymmetric discrete-dimers or a 1D chain of s led to red emission ( = 610-636 nm) in crystals. Unlike in the solution phase showing one absorption band, in thin films and in crystals the transition from the S state to both the S state and S state becomes feasible.

The epidemiology of laboratory-confirmed Hepatitis B Virus infection in the general population of South Africa, 2016-2018.

Introduction: despite the introduction of the Hepatitis B Virus (HBV) vaccine in South Africa in 1995, HBV remains endemic. South Africa's HBV vaccine coverage for the third dose was 71% in 2015. Information on the HBV prevalence in South Africa in recent years is limited, therefore, we estimated HBV prevalence and described annual trends.